Stock Information
symbol line chart

USBCUSBC Inc

Upcoming Earnings

We were not able to find an announced earnings date for this symbol yet. Check back again later

Company Info

CEO

Philip A. Bosua

Location

Nevada, USA

Exchange

NYSE

Website

https://knowlabs.co

Summary

Know Labs, Inc.

Company Info

CEO

Philip A. Bosua

Location

Nevada, USA

Exchange

NYSE

Website

https://knowlabs.co

Summary

Know Labs, Inc.

AI Insights for USBC
4 min read

Quick Summary

USBC is listed in the provided fundamentals as USBC Inc, with a company description that corresponds to Know Labs, Inc. The company focuses on developing and commercializing proprietary spectroscopy-based technologies in the United States. Its core technology, referred to as Bio-RFID, is designed to direct electromagnetic energy through a substance or material and capture a molecular signature. The company appears to be focused on measurement, sensing, and control applications, with healthcare and non-invasive diagnostics as likely target markets. Its main customers are likely to include medical device partners, healthcare providers, research organizations, and potentially consumers if the technology is eventually commercialized in wearable or diagnostic products.

Strengths

•

USBC’s primary strength is its potentially differentiated Bio-RFID technology platform.

•

A successful non-invasive molecular sensing approach could be valuable in healthcare, diagnostics, industrial measurement, and consumer health applications.

•

The company’s small size may allow it to focus intensely on core technology development and adapt quickly to new findings.

•

Its market capitalization suggests investors already assign value to its intellectual property and future optionality despite the lack of current revenue.

•

If the technology is validated, USBC could become an attractive partner or acquisition candidate for larger medical device, diagnostics, or sensor companies.

Key Risks

•

The biggest risk is technology risk, because the company must prove that Bio-RFID can deliver accurate, repeatable, and clinically useful measurements.

•

Regulatory risk is also significant if the company targets medical applications that require FDA clearance or approval.

•

Financial risk is high because the company is losing money and has no reported revenue in the provided data.

•

Competitive risk is substantial because established companies such as Dexcom, Abbott, and Medtronic already dominate important monitoring markets.

What to Watch

In the most recent reported quarter, the company showed characteristics of a pre-revenue or very early commercialization business.
Total revenue and total gross profit were listed as zero, while total operating income was negative at approximately $16.4 million.
Net income was negative at approximately $20.8 million, showing continued losses as the company develops its technology.
The company had only 20 employees, which suggests a small organization focused on research, development, intellectual property, and strategic execution.
No next earnings date, next dividend, or dividend streak was provided, and the company does not currently appear to return cash to shareholders through dividends.

Price Drivers

•

USBC’s stock price is likely driven more by development milestones and investor expectations than by current operating performance.

•

The provided fundamentals show no total revenue, no gross profit, negative operating income, and negative net income, which makes traditional earnings-based valuation difficult.

•

The company’s diluted EPS is negative at -0.05, and its earnings yield is listed as zero, indicating that profitability is not currently supporting the valuation.

•

Market sentiment toward small-cap speculative technology and medical device names can have a large impact, especially with a beta of 1.488.

•

News confusion around the USBC ticker, including unrelated items about U.S.

•

Bancorp, USB-C charging, bowling, and digital dollars, may also create noise that investors should separate from company-specific fundamentals.

Recent News

•

The recent news feed includes a reported strategic triparty partnership involving USBC, Uphold, and Vast Bank to advance regulated tokenized U.S. bank deposits.

•

However, this news appears inconsistent with the provided company description for Know Labs, which focuses on spectroscopy and Bio-RFID technology.

•

Other news items in the feed discuss U.S.

•

Bancorp earnings, USD Coin, USB-C charging, bowling broadcasts, and the history of USB technology, many of which do not appear directly related to this company.

•

Because of this mismatch, investors should verify whether the news belongs to the same ticker, a renamed entity, or an unrelated symbol with similar wording.

•

Based strictly on the fundamentals, the most relevant company-specific story remains the development and commercialization of Bio-RFID sensing technology.

Market Trends

•

Several broader market trends affect USBC’s prospects.

•

In healthcare, there is strong demand for less invasive, more convenient, and more continuous monitoring tools, especially for chronic diseases such as diabetes.

•

Investors are also interested in sensor innovation, wearable health devices, personalized medicine, and AI-enabled diagnostics.

•

At the same time, small-cap speculative technology stocks can be pressured by high interest rates, tighter financing conditions, and reduced appetite for unprofitable growth companies.

•

The company’s success will depend on whether it can convert favorable health-technology trends into validated products, regulatory progress, and eventual revenue.

AI-generated summary for educational purposes only. Not investment advice. Always do your own research before investing.

Community Research

Research from investors like you

Be the first to share your analysis on USBC

Help fellow investors make informed decisions by sharing your research on fundamentals, catalysts, and outlook.

Topics: Company overview • Products • Competitors • Strengths & Risks

Symbol's posts

No more topics to show